Literature DB >> 18358837

Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner.

Hayato Suzuki1, Masayuki Kurooka, Yoko Hiroaki, Yoshinori Fujiyoshi, Yasufumi Kaneda.   

Abstract

We previously reported that inactivated Sendai virus particle (hemagglutinating virus of Japan envelope; HVJ-E) has anti-tumor effects by eliciting IL-6 production in dendritic cells (DCs). In the present study, we investigated which components of HVJ-E elicit IL-6 production. HVJ-E containing F0 protein inactive for virus envelope-cell membrane fusion enhanced IL-6 production. Reconstituted liposomes containing F protein stimulated IL-6 production. The antibody against F protein inhibited IL-6 secretion by HVJ-E. When carbohydrate chains of the F glycoprotein were removed, HVJ-E lost the ability to stimulate IL-6 secretion. These results suggest that F glycoprotein is required for IL-6 production in DCs.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18358837     DOI： 10.1016/j.febslet.2008.03.011

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  10 in total

1.  Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.

Authors:  Masahide Matsuda; Keisuke Nimura; Takashi Shimbo; Toshimitsu Hamasaki; Tetsuya Yamamoto; Akira Matsumura; Yasufumi Kaneda
Journal:  J Neurooncol       Date:  2010-08-22       Impact factor: 4.130

2.  Mechanisms of Oncolysis by Paramyxovirus Sendai.

Authors:  O V Matveeva; G V Kochneva; S V Netesov; S B Onikienko; P M Chumakov
Journal:  Acta Naturae       Date:  2015 Apr-Jun       Impact factor: 1.845

3.  Inactivated Sendai Virus (HVJ-E) Immobilized Electrospun Nanofiber for Cancer Therapy.

Authors:  Takaharu Okada; Eri Niiyama; Koichiro Uto; Takao Aoyagi; Mitsuhiro Ebara
Journal:  Materials (Basel)       Date:  2015-12-26       Impact factor: 3.623

4.  Salmonella mediated the hemagglutinating virus of Japan-envelope transfer suppresses tumor growth.

Authors:  Che-Hsin Lee; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Oncotarget       Date:  2017-05-23

5.  Cancer immunotherapy using the Fusion gene of Sendai virus.

Authors:  Jiayu A Tai; Chin Yang Chang; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Cancer Gene Ther       Date:  2019-08-06       Impact factor: 5.987

Review 6.  Virosome presents multimodel cancer therapy without viral replication.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Biomed Res Int       Date:  2013-12-04       Impact factor: 3.411

7.  Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.

Authors:  Olga V Matveeva; Zong S Guo; Svetlana A Shabalina; Peter M Chumakov
Journal:  Mol Ther Oncolytics       Date:  2015-07-22       Impact factor: 7.200

Review 8.  Oncolytic Sendai virus-based virotherapy for cancer: recent advances.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Oncolytic Virother       Date:  2015-10-01

9.  Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer.

Authors:  Kazutoshi Fujita; Taigo Kato; Koji Hatano; Atsunari Kawashima; Takeshi Ujike; Motohide Uemura; Ryoichi Imamura; Koji Okihara; Osamu Ukimura; Tsuneharu Miki; Toshihiro Nakajima; Yasufumi Kaneda; Norio Nonomura
Journal:  Cancer Sci       Date:  2020-03-19       Impact factor: 6.716

Review 10.  Syncytia Formation in Oncolytic Virotherapy.

Authors:  Chase Burton; Eric Bartee
Journal:  Mol Ther Oncolytics       Date:  2019-10-01       Impact factor: 7.200
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.